Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

Abstract Background No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigate the long-term efficacy and safety of bosentan fo...

Full description

Bibliographic Details
Main Authors: Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Pulmonary Medicine
Subjects:
Pulmonary hypertension
Idiopathic pulmonary fibrosis
Right heart catheterization
Echocardiography
Endothelin receptor antagonists
Online Access:http://link.springer.com/article/10.1186/s12890-017-0523-2

Internet

http://link.springer.com/article/10.1186/s12890-017-0523-2

Similar Items